WebApr 6, 2024 · BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an … WebFeb 23, 2024 · BioCryst (BCRX) delivered earnings and revenue surprises of -29.03% and 2.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Historical Prices
WebGlobeNewswire. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral … WebMar 31, 2024 · BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. graf orlock merch
BioCryst to Present at Upcoming Investor Conferences BCRX Stock News
WebNov 1, 2024 · Despite the increases in sales of Orladeyo, the company's stock finished Tuesday down 11 percent, around $11.86 a share. This is down nearly 16 percent from the beginning of the year, and below ... WebApr 6, 2024 · finance.yahoo.com - February 21 at 9:36 AM. Why BioCryst Pharmaceuticals Stock Is Sliding Today. benzinga.com - February 21 at 9:36 AM. BioCryst Pharmaceuticals Non-GAAP EPS of -$0.38 misses by $0.18, revenue of $79.5M beats by $5.32M. msn.com - February 21 at 9:36 AM. china bus drive over cars